An evaluation of patritumab deruxtecan for the treatment of EGFR -mutated non-small cell lung cancer

Patients with advanced EGFR-mutant NSCLC who have received TKI therapy and chemotherapy have limited treatment options. Patritumab deruxtecan demonstrates clinical activity in this population with manageable side effects, addressing an unmet need for patients.